Society guideline links: Monoclonal gammopathy of undetermined significance

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Multiple myeloma" and "Society guideline links: Immunoglobulin light chain (AL) amyloidosis" and "Society guideline links: Waldenström macroglobulinemia".)

International

●International Myeloma Working Group (IMWG): Recommendations for the treatment of multiple myeloma-related bone disease (2021)

●IMWG: Consensus recommendations on imaging in monoclonal plasma cell disorders (2019)

●International Workshops on Waldenström Macroglobulinaemia (IWWM): Consensus panel recommendations for investigation and management of IgM and Waldenström-associated peripheral neuropathies (2017)

●IMWG: Criteria for the diagnosis of multiple myeloma, update (2014)

●IMWG: Consensus perspectives risk factors for progression and guidelines for monitoring and management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma (2010)

●IMWG: Guidelines for serum-free light chain analysis in multiple myeloma and related disorders (2009)

Canada

●Choosing Wisely Canada: Don't request a serum protein electrophoresis in asymptomatic patients in the absence of otherwise unexplained hypercalcemia, renal insufficiency, anemia or lytic bone lesions (updated 2020)

●Myeloma Canada Research Network (MCRN): Consensus guidelines on the diagnosis of multiple myeloma and related disorders (2020)

Europe

●European Myeloma Network (EMN): Recommendations on the clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders (2014)

●European Federation of Neurological Societies (EFNS)/Peripheral Nerve Society (PNS): Guideline on management of paraproteinemic demyelinating neuropathies – First revision (2010)

United Kingdom

●UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): Guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS) (2009)

India

●Indian Council of Medical Research (ICMR): Consensus document for management of multiple myeloma (2017)

Australia–New Zealand

●Medical Scientific Advisory Group to Myeloma Australia (MSAG MA): Clinical practice guideline on multiple myeloma, update (2019)

Japan

●[In Japanese] Japanese Society of Hematology (JSH): Hematopoietic tumor clinical practice guidelines, 2nd edition (2018, revised 2020)